Day: September 11, 2020

Downing ONE VCT plcLEI: 213800R88MRC4Y3OIW86Portfolio update11 September 2020The Company announces that the unaudited investment portfolio and net assets as at 31 July 2020 are summarised as follows:

                                                                                                                                                          Montrouge, 11 September 2020Crédit Agricole S.A. demonstrates commitment to the Panda market with its second 3-year CNY 1 billion benchmark bondSucceeding to its inaugural Panda Bond issuance in December 2019, Crédit Agricole S.A. has successfully issued its second CNY 1 billion (equivalent to € 123 million) senior preferred bond with a 3 year tenor and a 3.5% fixed rate. Crédit Agricole S.A. thus becomes a repeat issuer in the fast paced developing Panda Bond market, with the view to fund its activities in China and further diversify its long-term funding. The proceeds will be used to finance its wholly-owned banking subsidiary Crédit Agricole CIB (China) Limited in order to support...

   Crédit Agricole S.A. confirme son engagement sur le marché Panda avec sa seconde émission obligataire benchmark de 1 milliard de CNY à 3 ans.Suite à l’émission obligataire Panda inaugurale de décembre 2019, Crédit Agricole S.A. a réalisé avec succès sa seconde émission de titres senior préférés de maturité 3 ans au taux fixe de 3,5% pour un montant de 1 milliard de CNY (équivalent à 123 millions d’euros). Crédit Agricole devient ainsi un émetteur régulier sur le marché obligataire Panda en plein essor, afin de financer ses activités en Chine et diversifier davantage son financement à long terme. Le produit de cette émission servira à financer sa filiale bancaire chinoise entièrement détenue, Crédit Agricole CIB (China) Limited, pour lui permettre de répondre aux besoins de sa clientèle internationale par le biais de financements et...

Publication on September 11, 2020, after market closingRegulated information – transparency notificationEVS Broadcast Equipment S.A.: Euronext Brussels (EVS.BR), Bloomberg (EVS BB), Reuters (EVSB.BR)Publication of a transparency notification

Publication le 11 septembre 2020, après la fermeture du marchéInformation réglementée – notification de transparenceEVS Broadcast Equipment SA: Euronext Bruxelles (EVS.BR), Bloomberg (EVS BB), Reuters (EVSB.BR)Publication relative à une notification de transparence

— Data for Investigational Gene Therapy Treatment NBIb-1817 (VY-AADC) Presented at the MDS Virtual Congress 2020 —NBIb-1817 Treatment Showed Sustained Improvement in Motor Function, Including Greater “On” Time without Troublesome Dyskinesia and Reduction in Unified Parkinson’s Disease Rating Scale (UPDRS) Part III Scores, and Reduction in the Amount of Medications Up to Three Years in Patients with Parkinson’s Disease14 of 15 Patients Treated with NBIb-1817 Continued to Experience an Improvement in Disease Staging after Three Years, as Assessed by the Modified Hoehn & Yahr Scale Re-Initiation of Enrollment in Registrational RESTORE-1 Clinical Trial of NBIb-1817 Planned for Later this YearSAN DIEGO and CAMBRIDGE, Mass., Sept. 11, 2020 (GLOBE NEWSWIRE) — Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and Voyager Therapeutics,...

WINNIPEG, Manitoba, Sept. 11, 2020 (GLOBE NEWSWIRE) — (TSX: NWC):  The North West Company Inc. (the “Company” or “North West”) today reported its unaudited financial results for the second quarter ended July 31, 2020. It also announced that the Board of Directors have declared a dividend of $0.36 per share, an increase of $0.03 per share or 9.1%, to shareholders of record on September 30, 2020, to be paid on October 15, 2020 and that, subject to TSX approval,  the Company intends to commence a normal course issuer bid.

Post hoc EXPAND analysis showed improvements in cognitive processing speed in patients with active and non-active SPMS treated with Mayzent1 Subgroup analyses of the EXPAND trial showed the value of early treatment initiation with Mayzent in patients with active SPMS as positive effects on disability, cognitive processing speed and relapse outcomes were sustained for up to five years2 Results from EXCHANGE interim analysis presented at ACTRIMS-ECTRIMS reinforced its safety and tolerability profile when patients switched from an oral or injectable disease-modifying therapy (DMT) to Mayzent3The digital press release with multimedia content can be accessed here: Basel, September 11, 2020 — Novartis announced today that Mayzent® (siponimod) analyses from the Phase IIIb EXCHANGE and EXPAND trials showed Mayzent to be a safe treatment option...

SANTA CLARA, Calif., Sept. 11, 2020 (GLOBE NEWSWIRE) — AMD (NASDAQ:AMD) today announced that the company’s senior unsecured credit rating was raised to investment grade Baa3 by Moody’s Investors Service.  “Our focus on roadmap execution and financial discipline during the last five years has created a solid foundation for long-term growth,” said Devinder Kumar, senior vice president, CFO and Treasurer, AMD. “We are pleased with this upgrade from Moody’s, which reflects our strong financial performance and outlook for continued growth and significant cash generation.”Moody’s upgraded AMD based on growing business momentum, share gains, strong financial performance, excellent liquidity and consistent execution. About AMDFor 50 years, AMD has driven innovation in high-performance computing, graphics and visualization technologies –...